Wockhardt Share Price
2025.00+74.40 (+3.81%)
+36.09% past 1 Year
News
Wockhardt reports higher Q1 revenue on year over year basis
Equity
WOCKPHARMA
Wockhardt reports higher Q1 EBITDA and stronger margin year on year
Equity
WOCKPHARMA
Wockhardt reports Q1 consolidated net profit after prior year loss
Equity
WOCKPHARMA
Wockhardt gains US FDA approval for Zaynich antibiotic for cUTI therapy
Equity
WOCKPHARMA
Wockhardt: Q4 Revenue 965.00 Crores Rupees Vs 740.00 Crores (Yoy)
Equity
WOCKPHARMA
Wockhardt Q4 EBITDA Surges to Rs 225 Crores, Margin Expands to 23.3% YoY
Equity
WOCKPHARMA
Wockhardt Reports Q4 Consolidated Net Profit of Rs 166 Crores vs YoY Loss.
Equity
WOCKPHARMA
Wockhardt's Zaynich Receives Positive CDSCO Expert Panel Nod for Gram-Negative Infection Treatment.
Equity
WOCKPHARMA
Wockhardt's Zaynich Receives CDSCO Expert Panel Approval for Gram-Negative Infections
Equity
WOCKPHARMA
Wockhardt Q3 FY2026 Results: Revenue Growth and Profitability Swing
Equity
WOCKPHARMA
Wockhardt Q3 FY2026 Results: EBITDA Growth Amid Consolidated Challenges
Equity
WOCKPHARMA
Wockhardt Q3 FY2026 Consolidated Net Profit Rises 321% YoY to Rs 59 Crores
Equity
WOCKPHARMA
Wockhardt Phase 3 Trial Success for Foviscu Antibiotic Demonstrates Clinical Efficacy
Equity
WOCKPHARMA
Wockhardt Submits WCK 5222 Marketing Application to EMA, Granted Accelerated Assessment.
Equity
WOCKPHARMA
Wockhardt Targets European EMA Approval for Zaynich Antibiotic by July-August 2026.
Equity
WOCKPHARMA
Wockhardt Receives EMA Fast-Track Designation for WCK 5222 Antibiotic Targeting Drug-Resistant Infections.
Equity
WOCKPHARMA
Wockhardt forms three new overseas step-down subsidiaries in Switzerland, USA
Equity
WOCKPHARMA
Wockhardt reports strong Q2 results with robust growth in domestic biotech business, expanding global reach.
Equity
WOCKPHARMA
Q2 FY26 result: Wockhardt reports year-on-year revenue decline to Rs 782 crores.
Equity
WOCKPHARMA
Wockhardt Q2 FY25 EBITDA rises to Rs 178 crore, margin expands sharply YoY.
Equity
WOCKPHARMA